Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040027/S099

GORE VIATORR TIPS Endoprosthesis with Controlled Expansion

W. L. Gore & Associates, Inc. · Decision date Oct 27, 2025

FDA DECISIONP040027/S099

What did the FDA approve?

FDA records P040027/S099 as a supplement to PMA P040027, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 27, 2025.

FDA approval order statement

approval for a modification to the controlled expansion sleeve that allows the device to have a 6-10 mm adjustable diameter range (as opposed to the existing 8-10 mm diameter range)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Oct 27, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P040027/S099
Regulatory pathway
PMA supplement
Product code
MIR
Decision code
APPR
Decision date
Oct 27, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS.

Product code
MIR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040027/S099 received

    Application receipt date recorded by FDA.

  2. P040027/S099 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P040027. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MIR

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementOct 23, 2026FDA
Bard Peripheral Vascular, Inc.PMA approvalSep 25, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
32360 N. N. Valley Pkwy., Phonix, AZ, 85085

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records